Literature DB >> 16564914

Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma.

Anne F Buckley1, Lawrence J Burgart, Sanjay Kakar.   

Abstract

Increased expression of epidermal growth factor receptor (EGFR), a transmembrane tyrosine kinase, is associated with tumor progression in many carcinomas. Epidermal growth factor receptor inhibitors have shown promise in treating some of these tumors. Fibrolamellar hepatocellular carcinoma (FL-HCC) is an aggressive neoplasm that occurs in young patients with no history of cirrhosis. This study examines the expression and gene copy number of EGFR in FL-HCC. Formalin-fixed, paraffin-embedded FL-HCC (n = 13) sections were stained with a monoclonal antibody against EGFR. Fluorescence in situ hybridization analysis was performed using probes against EGFR gene and centromeric region of chromosome 7 (CEP 7). Epidermal growth factor receptor and CEP 7 signals were counted in 50 tumor nuclei per case as well as 300 normal hepatocyte nuclei. The EGFR to CEP 7 signal ratio was calculated for each case. Most (92%, 12/13) of FL-HCC showed strong and diffuse staining with anti-EGFR antibody. Fluorescence in situ hybridization was informative in 11 cases, 10 of which showed extra EGFR gene copy numbers (mean, 3.69; range, 3.13-5.0). Epidermal growth factor receptor was overexpressed in all these cases. The mean number of EGFR signals per cell in FL-HCC was double that of normal hepatocytes (3.69 versus 1.80); the mean EGFR/CEP 7 ratio in tumor cells was 1.05. In conclusion, EGFR is strongly overexpressed on the cell membrane in nearly all cases of FL-HCC. Similar gains of chromosome 7 are observed, indicating that the extra EGFR gene copies are due to polysomy rather than gene amplification. The strong expression of EGFR in FL-HCC tumors suggests that they may respond to treatment with EGFR antagonists.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16564914     DOI: 10.1016/j.humpath.2005.12.009

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  16 in total

1.  Genomic analysis of fibrolamellar hepatocellular carcinoma.

Authors:  Lei Xu; Florette K Hazard; Anne-Flore Zmoos; Nadine Jahchan; Hassan Chaib; Phillip M Garfin; Arun Rangaswami; Michael P Snyder; Julien Sage
Journal:  Hum Mol Genet       Date:  2014-08-13       Impact factor: 6.150

2.  Molecular characteristics of fibrolamellar hepatocellular carcinoma.

Authors:  Attila Patonai; Boglárka Erdélyi-Belle; Anna Korompay; Aron Somorácz; Péter Törzsök; Ilona Kovalszky; Tamás Barbai; Erzsébet Rásó; Gábor Lotz; Zsuzsa Schaff; András Kiss
Journal:  Pathol Oncol Res       Date:  2012-08-08       Impact factor: 3.201

3.  Histological and immediate postoperative outcome after preoperative cetuximab: case-matched control study.

Authors:  Patrick Pessaux; Ettore Marzano; Selenia Casnedi; Philippe Bachellier; Daniel Jaeck; Marie-Pierre Chenard
Journal:  World J Surg       Date:  2010-11       Impact factor: 3.352

4.  Unique genomic profile of fibrolamellar hepatocellular carcinoma.

Authors:  Helena Cornella; Clara Alsinet; Sergi Sayols; Zhongyang Zhang; Ke Hao; Laia Cabellos; Yujin Hoshida; Augusto Villanueva; Swan Thung; Stephen C Ward; Leonardo Rodriguez-Carunchio; Maria Vila-Casadesús; Sandrine Imbeaud; Anja Lachenmayer; Alberto Quaglia; David M Nagorney; Beatriz Minguez; Flair Carrilho; Lewis R Roberts; Samuel Waxman; Vincenzo Mazzaferro; Myron Schwartz; Manel Esteller; Nigel D Heaton; Jessica Zucman-Rossi; Josep M Llovet
Journal:  Gastroenterology       Date:  2014-12-31       Impact factor: 22.682

Review 5.  A framework for fibrolamellar carcinoma research and clinical trials.

Authors:  Timothy A Dinh; Alan F Utria; Kevin C Barry; Rosanna Ma; Ghassan K Abou-Alfa; John D Gordan; Elizabeth M Jaffee; John D Scott; Jessica Zucman-Rossi; Allison F O'Neill; Mark E Furth; Praveen Sethupathy
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-02-21       Impact factor: 73.082

6.  Chromogenic in situ hybridization analysis of Epidermal Growth Factor Receptor gene/chromosome 7 numerical aberrations in hepatocellular carcinoma based on tissue microarrays.

Authors:  Evangelos Tsiambas; Loukas Manaios; Costas Papanikolopoulos; Dimitrios N Rigopoulos; Dimitrios Tsounis; Andreas Karameris; Aspasia Soultati; Antigoni Koliopoulou; Christos Kravvaritis; Theodoros Sergentanis; Efstratios Patsouris; Spyridon Dourakis
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

7.  Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.

Authors:  Joshua N Honeyman; Elana P Simon; Nicolas Robine; Rachel Chiaroni-Clarke; David G Darcy; Irene Isabel P Lim; Caroline E Gleason; Jennifer M Murphy; Brad R Rosenberg; Lydia Teegan; Constantin N Takacs; Sergio Botero; Rachel Belote; Soren Germer; Anne-Katrin Emde; Vladimir Vacic; Umesh Bhanot; Michael P LaQuaglia; Sanford M Simon
Journal:  Science       Date:  2014-02-28       Impact factor: 47.728

8.  Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene.

Authors:  Benjamin Cieply; Gang Zeng; Tracy Proverbs-Singh; David A Geller; Satdarshan P S Monga
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

9.  Noninvasive radiofrequency ablation of cancer targeted by gold nanoparticles.

Authors:  Jon Cardinal; John Robert Klune; Eamon Chory; Geetha Jeyabalan; John S Kanzius; Michael Nalesnik; David A Geller
Journal:  Surgery       Date:  2008-08       Impact factor: 3.982

Review 10.  Role of Wnt/β-catenin signaling in liver metabolism and cancer.

Authors:  Satdarshan Pal Singh Monga
Journal:  Int J Biochem Cell Biol       Date:  2009-09-09       Impact factor: 5.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.